Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Breast Cancer

Highly purified CD34+ cells isolated using magnetically activated cell selection provide rapid engraftment following high-dose chemotherapy in breast cancer patients

Bone Marrow Transplantation volume 25, pages 243–249 (2000)Cite this article

Abstract

The primary objective of this study was to evaluate the safety of infusion of CD34+ cells, selected using a clinical scale magnetically activated cell sorting device, assessed by time to hematological engraftment and incidence of adverse events. Secondary objectives included evaluation of device performance in terms of purity and recovery of the CD34+ cell product. Breast cancer patients suitable for transplantation received cyclophosphamide and filgrastim for mobilisation, followed by three leukaphereses. The products of the first two leukaphereses underwent CD34+ cell selection. The product of the third leukapheresis was cryopreserved unmanipulated. Following high-dose cyclophosphamide, thiotepa and carboplatin, selected CD34+ cells were infused. In 54 patients who received selected cells only, the median time to platelet recovery and neutrophil recovery was 11 days (range 5–51) and 9 days (range 5–51), respectively. There were no adverse events associated with infusion of selected cells. A total of 126 leukapheresis samples was available before and after selection for central CD34+ analysis. The median purity was 96.1% (27.4–99.4) and the median recovery was 52.3% (15.2–146.3). These data show that cells selected using magnetically activated cell selection provide safe and rapid engraftment after high-dose therapy. Bone Marrow Transplantation (2000) 25, 243–249.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

Similar content being viewed by others

References

  1. Somlo G, Doroshow J, Forman S et al. High-dose chemotherapy and stem cell rescue for the treatment of primary high-risk breast cancer: prognostic indicators of overall survival and progression-free survival Proc Am Soc Clin Oncol 1995 14: 113 (Abstr 150)

    Google Scholar 

  2. Antman K, Ayash L, Elias A et al. A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in woman with measurable advanced breast cancer responding to standard-dose chemotherapy J Clin Oncol 1992 10: 102–110

    Article  CAS  PubMed  Google Scholar 

  3. Ross AA, Cooper BW, Lazarus HM et al. Detection and viability of tumor cells in peripheral blood stem cell collections from breast cancer patients using immunocytochemical and clonogenic assay techniques Blood 1993 82: 2605–2610

    CAS  PubMed  Google Scholar 

  4. Ross AA, Loudovaris M, Hazelton B et al. Immunocytochemical analysis of tumor cells in pre- and post-culture peripheral blood progenitor cell collections from breast cancer patients Exp Hematol 1995 23: 1478–1483

    CAS  PubMed  Google Scholar 

  5. Brugger W, Bross KJ, Glatt M et al. Mobilization of tumor cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors Blood 1994 83: 636–640

    CAS  PubMed  Google Scholar 

  6. Berenson RJ, Bensinger WI, Kalamasz D et al . Avidin–biotin immunoadsorption: a technique to purify cells and its potential applications. In: Gale RP, Champlin R (eds) Progress in Bone Marrow Transplantation Liss: New York 1987 pp 423–428

    Google Scholar 

  7. Stroncek DF, Fautsch SK, Lasky LC et al. Adverse reactions in patients transfused with cryopreserved marrow Transfusion 1991 31: 521–526

    Article  CAS  PubMed  Google Scholar 

  8. Styler MJ, Topolsky DL, Crilley PA et al. Transient high grade heart block following autologous bone marrow infusion Bone Marrow Transplant 1992 10: 435–438

    CAS  PubMed  Google Scholar 

  9. Shpall EJ, LeMaistre CF, Holland K et al. A prospective randomized trial of buffy coat versus CD34-selected autologous bone marrow support in high-risk breast cancer patients receiving high-dose chemotherapy Blood 1997 90: 4313–4320

    CAS  PubMed  Google Scholar 

  10. Miltenyi S, Guth S, Radbruch A et al . Isolation of CD34+ hematopoietic progenitor cells by high-gradient magnetic cell sorting (MACS) Hematopoietic Stem Cells: The Mulhouse Manual 1994 pp 201–213

  11. Kato K, Radbruch A . Isolation and characterization of CD34+ hematopoietic stem cells from human peripheral blood by high-gradient magnetic cell sorting Cytometry 1993 14: 384–392

    Article  CAS  PubMed  Google Scholar 

  12. Miltenyi S, Müller W, Weichel W, Radbruch A . High-gradient magnetic cell separation with MACS Cytometry 1990 11: 231–238

    Article  CAS  PubMed  Google Scholar 

  13. Wynter de EA, Coutinho LH, Pei X et al. Comparison of purity and enrichment of CD34+ cells from bone marrow, umbilical cord and peripheral blood (primed for apheresis) using five separation systems Stem Cells 1995 13: 524–532

    Article  Google Scholar 

  14. McNiece I, Briddell R, Stoney G et al. Large-scale isolation of CD34+ cells using the Amgen Cell Selection Device results in high levels of purity and recovery J Hematother 1997 6: 1–11

    Article  Google Scholar 

  15. Johnsen HE, Baech J, Nikolajsen K for the Nordic Stem Cell Laboratory Group . Validation of the Nordic flow cytometry standard for CD34+ cell enumeration in blood and autografts: report from the Third workshop J Hematother 1999 8: 15–28

    Article  CAS  PubMed  Google Scholar 

  16. Somlo G, Sniecinski I, Odom-Maryon T et al. Effect of CD34+ selection and various schedules of stem cell reinfusion and granulocyte colony-stimulating factor priming on hematopoietic recovery after high-dose chemotherapy for breast cancer Blood 1997 89: 1521–1528

    CAS  PubMed  Google Scholar 

  17. Brugger W, Henschler R, Heimfeld S et al. Positively selected autologous blood CD34+ cells and unseparated peripheral blood progenitor cells mediate identical hematopoietic engraftment after high-dose VP16, ifosfamide, carboplatin and epirubicin Blood 1994 84: 1421–1426

    CAS  PubMed  Google Scholar 

  18. Weaver CH, Hazelton B, Birch R et al. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy Blood 1995 86: 3961–3969

    CAS  PubMed  Google Scholar 

  19. Elias AD, Ayash L, Anderson KC et al. Mobilization of peripheral blood progenitor cells by chemotherapy and granulocyte–macrophage colony-stimulating factor for hematological support after high-dose intensification for breastcancer Blood 1992 79: 3036–3044

    CAS  PubMed  Google Scholar 

  20. Gorin NC, Aegerter P, Auvert B et al. Autologous bone marrow transplantation for acute myelocytic leukaemia in first remission: a European survey of the role of marrow purging Blood 1990 75: 1606–1614

    CAS  PubMed  Google Scholar 

  21. Van Hoef M, Moseley A . Selective CD5/CD8 T-cell subset depletion by the AIS Cellectors CD5/CD8 in mis-matched and unrelated allogeneic bone marrow transplantation J Hematother 1995 63: 209 (Abstr.)

    Google Scholar 

  22. Hénon PR, Liang H, Beckwirth G et al. Comparison of hemopoietic and immune recovery after autologous bone marrow or blood stem cell transplants Bone Marrow Transplant 1992 9: 285–291

    PubMed  Google Scholar 

  23. Roberts MM, To LB, Gillis D et al. Immune reconstitution following peripheral blood stem cell transplantation, autologous bone marrow transplantation and allogeneic bone marrow transplantation Bone Marrow Transplant 1993 12: 469–475

    CAS  PubMed  Google Scholar 

  24. Bomberger C, Singh-Jairam M, Rodey G et al. Lymphoid reconstitution after autologous PBSC transplantation with FACS-sorted CD34+ hematopoietic progenitors Blood 1998 91: 2588–2600

    CAS  PubMed  Google Scholar 

  25. Di-Nicola M, Siena S, Corradini P et al. Elimination of bcl-2-IgH-positive follicular lymphoma cells from blood transplants with high recovery of hematopoietic progenitors by the Miltenyi CD34+ cell sorting system Bone Marrow Transplant 1996 18: 1117–1121

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We wish to thank K Zilm, B Kern, C Brunard and G Stoney for their technical assistance with the CD34+ analysis and R Mazenet and D Rectenwald for their support throughout the study.

Author information

Authors and Affiliations

  1. Medisch Spectrum Twente, Enschede, The Netherlands

    DJ Richel, MR Schaafsma & C Schenkeveld

  2. Herlev Hospital, Copenhagen, Denmark

    HE Johnsen & SW Hansen

  3. St Luc Hospital, Brussels, Belgium

    J Canon, T Guillaume & M Symann

  4. Amgen Inc, Thousand Oaks, CA, USA

    I McNiece, AJ Gringeri & R Briddell

  5. Amgen Limited, Cambridge, UK

    C Ewen, R Davies & J Freeman

  6. AmCell GmbH, Cologne, Germany

    S Miltenyi

Authors
  1. DJ Richel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. HE Johnsen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J Canon
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. T Guillaume
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. MR Schaafsma
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. C Schenkeveld
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. SW Hansen
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. I McNiece
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. AJ Gringeri
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. R Briddell
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. C Ewen
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. R Davies
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. J Freeman
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. S Miltenyi
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. M Symann
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Richel, D., Johnsen, H., Canon, J. et al. Highly purified CD34+ cells isolated using magnetically activated cell selection provide rapid engraftment following high-dose chemotherapy in breast cancer patients. Bone Marrow Transplant 25, 243–249 (2000). https://doi.org/10.1038/sj.bmt.1702136

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1702136

Keywords

This article is cited by

Search

Advanced search

Quick links